Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Friday, December 23, 2011

Soluble form of human FMO3 for 'in vitro' experiments

Regular readers will know that the enzyme flavin mono-oxygenase isoform 3 (FMO3) is of particular interest to MEBO, given that it oxidizes many 'smelly' sulfide and amine compounds (and is 'officially' recognised as being the enzyme at fault for trimethylaminuria). Since enzymes deal with particular chemical structures, this means it deals with compounds that can be sourced from various sources; such as the gut flora, internally produced 'biogenic' amines (eg hormones etc), and drugs.

In the pharmacology industry FMO3 would be referred to as a 'drug metabolizing enzyme', partly because they will be trying to understand how their drug is metabolized in humans to 'help' them, and partly because they will afraid of future lawsuits due to bad reactions. Probably most understanding of the 'drug metabolizing enzymes' is discovered for these reasons.

FMO3 seems to have been the 'neglected' enzyme in this group of enzymes, but it seems it is finally getting some attention. So it is good to see that some researchers have come up with a form of FMO3 that seems to be easier to do 'in vitro' (analogy : in a test tube). It seems to be a soluble form that is easier for researchers to work with. Let's hope it is a technical leap of some sorts.

...The use of this soluble form of the hFMO3 enzyme as opposed to the usual microsomal preparations is advantageous for in vitro drug metabolism studies that are a requirement in the early phases of drug development by pharmaceutical industry.

Pubmed abstract : In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3
Other FMO3 links
Flavin Mono Oxygenase : The other oxidase
Wikipedia : FMO enzyme family
FMO enzyme family : Structure, polymorphisms and role in drug metabolism


Post a Comment